PLoS ONE · 2015 · 61 citations · 11 references
MedicineOncologyPathologyBreast OncologyMolecular OncologyNeoplasiaBreast Cancer OncologyHer2-positive Breast CancerImmunohistochemistryCopy Number ProfilingFluorescent In Situ HybridizationGene Copy Number AnalysisGene Copy Number EffectsHer2 AmplificationHer2 ExpressionHer2 Gene AmplificationHuman Epidermal Growth Factor Receptor 2 (Her2) Expression
INTRODUCTION: The latest guidelines of the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) to test Human Epidermal Growth Factor Receptor 2 (HER2) in breast cancer after being revised in 2008 underwent a second modification in October 2013. The modification includes changes in cut-offs: 10% strong membranous staining for score 3+ on immunohistochemistry (IHC) (previously 30%) and using the ratio of >2 or absolute gene-copy-number (6 or more) alone or in combination with each other by in-situ-hybridisation technology (previously >2.2 and average copy-number of 6 or more). Hereby we addressed the question, which impact the modified cut-offs had on overall HER2-positivity in a single institution. METHODS: We prospectively analysed 617 consecutive diagnostic breast-cancer cases which underwent double HER2 testing by immunohistochemistry and fluorescent in-situ hybridisation (FISH), using the modified 2013 ASCO/CAP-guidelines for one year (October 2013-October 2014). Results were compared with HER2-test results on 1,528 consecutive diagnostic breast-cancer cases from two previous years (2011-2012), using the 2008 ASCO/CAP guidelines, also tested with IHC and FISH in each case. RESULTS: Between October 2013 and October 2014, overall HER2-positivity was 15.8% (98 of 617 cases were either IHC 3+ or FISH amplified). 79 of 617 cases (13%) were IHC 3+, 96 of 617 cases (15.5%) were FISH amplified. Equivocal cases were seen in 25 of 617 cases (4.1%). 22 of 25 equivocal cases (88%) in 2013-2014 were IHC 1+ or 2+. In 13 equivocal cases, there was a repeated IHC/FISH testing: 2 of 13 cases (15%) became FISH amplified, 1 of 13 cases (7.5%) became IHC 3+. In 2011-2012, overall HER2-positivity (IHC/FISH) was 13.8% (211 of 1,528 cases). 185 of 1,528 cases (12%) were 3+ on IHC, 181 of 1,522 cases (12%) were amplified by FISH. Six of 1,528 cases were equivocal by FISH, and interpreted as non-amplified (0.3%). CONCLUSIONS: Applying the modified ASCO/CAP guidelines from 2013 resulted in an increase (2%) in overall HER2-positivity rate compared to overall-HER2-positivity rate using the 2008 ASCO/CAP guidelines. The increased positivity rate was mainly due to more FISH-positive cases (3.5% more than until 2013). The high rate of equivocal cases (4.1%) did not contribute to increase in overall HER2-positivity, but resulted in delay in definitive HER2-status.
11
Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Journal of Clinical Oncology · 2006 · 4.5K citations · Full text
Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology · 2013 · 4.1K citations · Full text
Annette Lebeau, Daniela Deimling, Christine Kaltz et al. · Journal of Clinical Oncology · 2001 · 326 citations
Zsuzsanna Varga, Aurelia Noske, Constanze Ramach et al. · BMC Cancer · 2013 · 107 citations · Full text
Medicine, Oncology, Breast Oncology +14
Gillian Bethune, Daniel Veldhuijzen van Zanten, Rebecca F. MacIntosh et al. · Histopathology · 2015 · 63 citations
Medicine, Oncology, Pathobiology +17